

21 December 2023

Director/PDMR Dealings

The Board of Atlantic Lithium Limited (AIM: ALL, ASX: A11, OTCQX: ALLIF, "Atlantic Lithium" or the "Company"), the African-focused lithium exploration and development company targeting to deliver Ghana's first lithium mine, wishes to advise that Finance Director and Company Secretary Amanda Harsas, as a Director and person discharging managerial responsibilities ("PDMR") of the Company, has purchased in the market a total of 100,000 ordinary shares of no par value each ("Ordinary Shares"), equating to an aggregate value of A\$39,437 (£20,987), as follows:

Director / PDMR Role	Number of Ordinary Shares purchased	Resultant number of Ordinary Shares beneficially held	Resultant percentage of issued share capital beneficially held
Ms Amanda Harsas <i>Finance Director and Company Secretary</i>	100,000	4,300,000	0.70%

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

TABLE 1 - PURCHASE OF ORDINARY SHARES

1.	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name:	Amanda Harsas	
2.	Reason for the notification		
a)	Position/status:	Finance Director and Company Secretary	
b)	Initial notification/Amendment:	Initial notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name:	Atlantic Lithium Limited	
b)	LEI:	213800H1JY3J7BB6BN06	
4.	1. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.		
a)	Description of the financial instrument, type of instrument: Identification code:	Ordinary Shares of no par in the Company ISIN: AU0000237554	
b)	Nature of the transaction:	Purchase of Ordinary Shares	
c)	Price(s) and volume(s):	Price(s)	Volume(s)
		AUD0.3943	100,000
d)	Aggregated information:	Purchase of 100,000 Ordinary Shares at an average price of GBP0.2098 (AUD0.3943) per Ordinary Share	

e)	Date of the transaction:	20 December 2023
f)	Place of the transaction:	ASX (A11)

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

For any further information, please contact:

Atlantic Lithium Limited

Neil Herbert (Executive Chairman)

Amanda Harsas (Finance Director and Company Secretary)



www.atlanticlithium.com.au



IR@atlanticlithium.com.au



Tel: +61 2 8072 0640



SP Angel Corporate Finance LLP
Nominated Adviser
Jeff Keating
Charlie Bouverat
Tel: +44 (0)20 3470 0470



Yellow Jersey PR Limited
Charles Goodwin
Bessie Elliot
atlantic@yellowjerseypr.com
Tel: +44 (0)20 3004 9512



Canaccord Genuity Limited
Financial Adviser:
Raj Khatri (UK) /
Duncan St John,
Christian Calabrese (Aust)

Corporate Broking:
James Asensio

Tel: +44 (0) 20 7523 4500

Notes to Editors:

About Atlantic Lithium

www.atlanticlithium.com.au

Atlantic Lithium is an AIM and ASX-listed lithium company advancing a portfolio of lithium projects in Ghana and Côte d'Ivoire through to production.

The Company's flagship project, the Ewoyaa Project in Ghana, is a significant lithium spodumene pegmatite discovery on track to become Ghana's first lithium-producing mine.

The Definitive Feasibility Study for the Project indicates the production of 3.6Mt of spodumene concentrate over a 12-year mine life, making it one of the top 10 largest spodumene concentrate mines in the world.

The Project, which was awarded a Mining Lease in October 2023, is being developed under a funding agreement with Piedmont Lithium Inc.

Atlantic Lithium holds 509km² and 774km² of tenure across Ghana and Côte d'Ivoire respectively, comprising significantly under-explored, highly prospective licences.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seq.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFIFSRFLLFIV